TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy (ECT) for Depression: Does it Improve Treatment Outcome?
Brief Summary: The main aim of this research is to ascertain whether Ketamine would be a more effective anaesthetic for Electroconvulsive Therapy (ECT) than the standard anaesthetic. In doing so the investigators aim to examine the effect of ketamine on ratings of depressive symptoms, the number of required ECT treatments, and the effect of this anaesthetic on memory.


Options:
A: Arm Label: Placebo then MK-0657; Type: EXPERIMENTAL; Interventions: Drug: MK-0657, Drug: Placebo | Arm Label: MK-0657 then Placebo; Type: EXPERIMENTAL; Interventions: Drug: MK-0657, Drug: Placebo | Intervention Type: DRUG; Name: MK-0657; Assigned to Arm(s): MK-0657 then Placebo, Placebo then MK-0657 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): MK-0657 then Placebo, Placebo then MK-0657
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Propofol
D: Arm Label: Part 1: Block A MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: Block B MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block B Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: Block C MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block C Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: Block D MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block D Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 2: MK-8777 200 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 2: MK-8777 800 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: MK-8777; Assigned to Arm(s): Part 1: Block A MK-8777, Part 1: Block B MK-8777, Part 1: Block C MK-8777, Part 1: Block D MK-8777, Part 2: MK-8777 200 mg, Part 2: MK-8777 800 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part 1: Block A Placebo, Part 1: Block B Placebo, Part 1: Block C Placebo, Part 1: Block D Placebo, Part 2: Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Control Trial of Misoprostol Versus Placebo for Cervical Priming in IUD Insertion for Nulliparous Women
Brief Summary: The purpose of this study is to see if using misoprostol makes the intrauterine device insertion easier and less painful in women who have never had a baby.


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: LNG-IUS; Type: N/A; Interventions: Other: Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up. | Arm Label: Cu-IUD; Type: N/A; Interventions: Other: Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up. | Intervention Type: OTHER; Name: Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.; Assigned to Arm(s): Cu-IUD, LNG-IUS
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Magnesium Oxide | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DIETARY_SUPPLEMENT; Name: Magnesium Oxide; Assigned to Arm(s): Placebo
D: Arm Label: Placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo Gel | Arm Label: Nitroprusside Gel; Type: EXPERIMENTAL; Interventions: Procedure: Nitroprusside Gel | Intervention Type: PROCEDURE; Name: Nitroprusside Gel; Assigned to Arm(s): Nitroprusside Gel | Intervention Type: PROCEDURE; Name: Placebo Gel; Assigned to Arm(s): Placebo gel

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of a Brief Cognitive Behavioral Intervention Designed to Prevent and Reduce Symptoms of Posttraumatic Stress in Mothers of Preterm Infants.
Brief Summary: The purpose of the study includes:

1. To develop a treatment manual and pilot test this treatment intervention which is designed to prevent and reduce psychological distress in parents who have infants hospitalized in the neonatal intensive care unit (NICU).
2. To conduct a treatment intervention study in which parents of NICU infants will receive a 6-12 session treatment designed to reduce psychological distress, and to compare outcomes with parents who do not receive the intervention.

We hope to learn whether or not a simple psychotherapeutic and psychoeducational intervention offered to parents of NICU infants can prevent or minimize the development of symptoms of psychological distress in parents, including symptoms of anxiety and depression and posttraumatic stress disorder (PTSD).


Options:
A: Arm Label: Cognitive Behavior Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavior therapy | Arm Label: Placebo comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavior therapy; Assigned to Arm(s): Cognitive Behavior Therapy
B: Arm Label: Education group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education | Arm Label: Standard mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: standard mindfulness | Arm Label: Mobile mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: mobile mindfulness | Intervention Type: BEHAVIORAL; Name: mobile mindfulness; Assigned to Arm(s): Mobile mindfulness | Intervention Type: BEHAVIORAL; Name: standard mindfulness; Assigned to Arm(s): Standard mindfulness | Intervention Type: BEHAVIORAL; Name: education; Assigned to Arm(s): Education group
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Prolonged Exposure (PE) Therapy | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure (PE) Therapy; Assigned to Arm(s): 2
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Diary | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Diary; Assigned to Arm(s): Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Remote Monitoring and Contingency Management Reinforcement for Alcohol Abstinence
Brief Summary: This pilot project proposes to monitor real-world alcohol use using a novel technology-cell phone videorecordings in conjunction with breathalyzer recordings-and to conduct a small randomized study of this technology for reinforcing alcohol abstinence. Individuals with frequent alcohol use (N = 30) will be asked to carry a study cell phone plus a handheld breathalyzer for one month. Participants will be randomized to one of two conditions: alcohol monitoring or alcohol monitoring plus contingency management. In both conditions, research assistants will telephone participants on their cell phone an average of 10 times per week to request submission of a breathalyzer sample using the video monitoring function on the cell phone. Samples will be time and date stamped, and the video containing the breathalyzer result will be sent to study staff via the cell phone. Participants will be compensated for each video recorded within one hour of receiving the prompt. Participants randomized to the contingency management condition will receive the same alcohol monitoring described above, and they will also receive reinforcement for each alcohol negative breath sample submitted within one hour of the prompt. Data from this pilot project will be useful for (1) determining the feasibility of assessing alcohol use in the natural environment via breathalyzers and cell phone technology, and (2) estimating effect sizes of a CM intervention that reinforces alcohol abstinence using breathalyzers and cell phone technology. In an exploratory manner, we will also evaluate the reliability and validity of the video monitoring procedure and trends toward changes in psychosocial functioning.


Options:
A: Intervention Type: BEHAVIORAL; Name: Check Your Drinking (CYD); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Alcohol Help Centre (AHC); Assigned to Arm(s): N/A
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Check Your Drinking University version | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Check Your Drinking University version; Assigned to Arm(s): Intervention
C: Arm Label: Monitoring Alone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Monitoring plus contingency management for abstinence; Type: EXPERIMENTAL; Interventions: Behavioral: contingency management for abstinence | Intervention Type: BEHAVIORAL; Name: contingency management for abstinence; Assigned to Arm(s): Monitoring plus contingency management for abstinence
D: Arm Label: Promillekoll; Type: EXPERIMENTAL; Interventions: Behavioral: Promillekoll | Arm Label: PartyPlanner; Type: EXPERIMENTAL; Interventions: Behavioral: PartyPlanner | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Promillekoll; Assigned to Arm(s): Promillekoll | Intervention Type: BEHAVIORAL; Name: PartyPlanner; Assigned to Arm(s): PartyPlanner

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Web-Based Weight Loss & Weight Maintenance Intervention for Older Rural Women
Brief Summary: This project will evaluate an Internet delivery strategy to address weight loss and maintenance among rural midlife and older women.


Options:
A: Arm Label: Group 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Lifestyle Modification | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Behavioral: Lifestyle Modification | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Group 3, Group 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: BEHAVIORAL; Name: Lifestyle Modification; Assigned to Arm(s): Group 2, Group 4
B: Arm Label: SDT Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SDT and Motivational Interviewing in Obesity Treatment | Arm Label: Comparison Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SDT and Motivational Interviewing in Obesity Treatment; Assigned to Arm(s): SDT Intervention
C: Arm Label: Web-based only (WO) weight intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental: Web-based only (WO) weight intervention | Arm Label: WO & peer-led discussion board (WD); Type: EXPERIMENTAL; Interventions: Behavioral: Experimental: Web-based only (WO) weight intervention, Behavioral: Experimental: WO plus peer-led discussion board (WD) | Arm Label: WO & professional email counseling (WE); Type: EXPERIMENTAL; Interventions: Behavioral: Experimental: Web-based only (WO) weight intervention, Behavioral: Experimental: WO & professional email counseling (WE) | Intervention Type: BEHAVIORAL; Name: Experimental: Web-based only (WO) weight intervention; Assigned to Arm(s): WO & peer-led discussion board (WD), WO & professional email counseling (WE), Web-based only (WO) weight intervention | Intervention Type: BEHAVIORAL; Name: Experimental: WO plus peer-led discussion board (WD); Assigned to Arm(s): WO & peer-led discussion board (WD) | Intervention Type: BEHAVIORAL; Name: Experimental: WO & professional email counseling (WE); Assigned to Arm(s): WO & professional email counseling (WE)
D: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM-IV-TR Schizophrenia
Brief Summary: The purpose of this study is to determine whether at least 1 dose level of LY2140023 given to acutely ill patients with schizophrenia will demonstrate significantly greater efficacy as compared to placebo.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: asenapine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Intervention Type: DRUG; Name: asenapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): 3
B: Arm Label: 80 milligrams (mg) LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 40 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 10 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 mg LY2140023, BID, 40 mg LY2140023, BID, 80 milligrams (mg) LY2140023, BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 10 milligrams (mg) LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 80 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 160 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 milligrams (mg) LY2140023, 160 mg LY2140023, 80 mg LY2140023 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): LY2140023 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM-IV-TR Schizophrenia
Brief Summary: The purpose of this study is to determine whether at least 1 dose level of LY2140023 given to acutely ill patients with schizophrenia will demonstrate significantly greater efficacy as compared to placebo.


Options:
A: Arm Label: Iloperidone; Type: EXPERIMENTAL; Interventions: Drug: Iloperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Iloperidone; Assigned to Arm(s): Iloperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 160 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 4 mg Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 80 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 4 mg Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 160 mg LY2140023, 80 mg LY2140023
C: Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): N/A
D: Arm Label: 80 milligrams (mg) LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 40 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 10 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 mg LY2140023, BID, 40 mg LY2140023, BID, 80 milligrams (mg) LY2140023, BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Gaining Further Understanding of the Underlying Mechanisms of Myocardial Function
Brief Summary: The main focus of the project is to determine to what degree myocardial energy metabolism is linked to impaired function in human cardiomyocytes, whether exercise training and remote ischemic preconditioning can restore cardiomyocyte function and whether this is linked to improved mitochondrial and cell function.


Options:
A: Arm Label: Remote ischemic preconditioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote ischemic preconditioning | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Control | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning; Assigned to Arm(s): Remote ischemic preconditioning | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control
B: Arm Label: ExerciseTr; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: Remote ischemic preconditioning group; Type: EXPERIMENTAL; Interventions: Procedure: remote ischemic preconditioning | Arm Label: Control patient group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): ExerciseTr | Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): Remote ischemic preconditioning group
C: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A
D: Arm Label: Flavanol rich cocoa; Type: EXPERIMENTAL; Interventions: Other: Cocoa | Arm Label: flavanol poor cocoa drink; Type: EXPERIMENTAL; Interventions: Other: Cocoa | Intervention Type: OTHER; Name: Cocoa; Assigned to Arm(s): Flavanol rich cocoa, flavanol poor cocoa drink

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Gaining Further Understanding of the Underlying Mechanisms of Myocardial Function
Brief Summary: The main focus of the project is to determine to what degree myocardial energy metabolism is linked to impaired function in human cardiomyocytes, whether exercise training and remote ischemic preconditioning can restore cardiomyocyte function and whether this is linked to improved mitochondrial and cell function.


Options:
A: Arm Label: ExerciseTr; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: Remote ischemic preconditioning group; Type: EXPERIMENTAL; Interventions: Procedure: remote ischemic preconditioning | Arm Label: Control patient group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): ExerciseTr | Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): Remote ischemic preconditioning group
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Intervention Type: PROCEDURE; Name: remote ischemic postconditioning; Assigned to Arm(s): 1, 2, 3
C: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RIPC, Drug: isoflurane+sufentanil anesthesia | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control, Drug: isoflurane+sufentanil anesthesia | Intervention Type: PROCEDURE; Name: RIPC; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: isoflurane+sufentanil anesthesia; Assigned to Arm(s): Control, RIPC
D: Arm Label: remote ischemic preconditioning; Type: EXPERIMENTAL; Interventions: Other: remote ischemic preconditioning (RIPC) | Intervention Type: OTHER; Name: remote ischemic preconditioning (RIPC); Assigned to Arm(s): remote ischemic preconditioning

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Culturally Adapted Manual Assisted Cognitive Behavioral Therapy for Prevention of Self Harm: A Randomized Control Trial
Brief Summary: Aim:

To adapt and develop a culturally appropriate psychological intervention and test its feasibility, and acceptability for the patients presenting to general hospital following self-harm in Karachi Pakistan.

Primary hypothesis:

Patients who receive cognitive behavioral therapy will show significant decrease in suicidal ideation as compared to patients with treatment as usual.

Design:

Randomized Control Trial

Setting:

Medical Departments of General Hospitals in Karachi.

Participants:

A total of 200 self harm patients will be randomized to psychological intervention and treatment as usual arm.

Intervention:

Culturally Adapted Cognitive Behavioral Therapy (CBT)

Outcome measure:

Beck Suicidal Ideation Scale


Options:
A: Arm Label: Teachable Moment Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Teachable Moment Brief Intervention (TMBI) | Arm Label: Treatment as Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Community Control Group (CCG); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Teachable Moment Brief Intervention (TMBI); Assigned to Arm(s): Teachable Moment Brief Intervention
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: Behavioral: Dialectical Cognitive Therapy | Intervention Type: BEHAVIORAL; Name: Dialectical Cognitive Therapy; Assigned to Arm(s): 1
C: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm
D: Arm Label: Priovi; Type: EXPERIMENTAL; Interventions: Behavioral: Priovi, Other: CAU | Arm Label: Care-as-Usual (CAU) / wait list; Type: ACTIVE_COMPARATOR; Interventions: Other: CAU | Intervention Type: BEHAVIORAL; Name: Priovi; Assigned to Arm(s): Priovi | Intervention Type: OTHER; Name: CAU; Assigned to Arm(s): Care-as-Usual (CAU) / wait list, Priovi

Answer: C